Klotho Peptides: Dosing Protocols
Dosing guidelines, reconstitution, and administration information
๐TL;DR
- โข2 dosing protocols documented
- โขReconstitution instructions included
- โขStorage: Store lyophilized peptides at -20 degrees C, protected from light and moisture. Reconstituted solutions should be aliquoted and stored at -20 degrees C to avoid freeze-thaw degradation. Follow supplier-specific storage recommendations.
Protocol Quick-Reference
Anti-fibrotic therapy for kidney disease (preclinical)
Dosing
Amount
Not standardized (preclinical IV/infusion doses)
Frequency
Single or chronic infusion (preclinical)
Duration
Acute to multiple weeks (study-dependent)
Administration
Route
IVTiming
KP1 administered as IV bolus in mouse fibrosis models. KP6 administered as chronic infusion in diabetic mouse models. No human dosing established.
Cycle
Duration
Study-dependent (acute to multiple weeks)
Repeatable
Single cycle
โ๏ธ Suggested Bloodwork (3 tests)
CMP (Comprehensive Metabolic Panel)
When: Baseline
Why: Kidney and liver function baseline
Urinalysis with protein
When: Baseline
Why: Assess proteinuria relevant to kidney disease applications
Serum phosphorus and calcium
When: Baseline
Why: Klotho regulates phosphate and calcium homeostasis
๐ก Key Considerations
- โPreclinical only: no human clinical trials have been conducted with klotho peptides
- โKP1 and KP6 are research reagents, not pharmaceutical products or supplements
- โFull-length klotho protein cognitive effects use the much larger KL1 domain, not short KP1/KP6 peptides
Unlock dosing protocols
Free access to research-backed dosing information for all peptides.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
| Purpose | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Preclinical Kidney Fibrosis (KP1 - Intravenous) | In mouse unilateral ureteral obstruction (UUO) models, KP1 was administered intravenously. Doses were not specified in standardized human-equivalent terms. KP1 showed preferential accumulation in injured kidneys after IV administration. | IV injection in preclinical models | Acute and short-term dosing in fibrosis models | Published in Nature Communications (2022). Not applicable to human use. Route and dose optimization for human application has not been determined. |
| Preclinical Diabetic Kidney Disease (KP6 - Chronic Infusion) | In diabetic mouse models (STZ-induced and db/db), KP6 was administered by chronic infusion. Treatment reversed established proteinuria and ameliorated glomerulosclerosis and interstitial fibrosis. | Chronic infusion in preclinical models | Multiple weeks in diabetic mouse models | Published in Kidney International (2022). Scrambled-sequence control peptide showed no effect, confirming sequence-specific activity. |
Unlock full dosage protocols
Free access to complete dosing tables and protocol details.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
๐Reconstitution Instructions
Research-grade klotho peptides (KP1, KP6) are supplied as lyophilized powder by specialty peptide suppliers. Reconstitute in sterile water or appropriate buffer according to supplier instructions. These are research reagents, not pharmaceutical products.
๐งStorage Requirements
Store lyophilized peptides at -20 degrees C, protected from light and moisture. Reconstituted solutions should be aliquoted and stored at -20 degrees C to avoid freeze-thaw degradation. Follow supplier-specific storage recommendations.
Community Dosing Protocols
Compare these clinical doses with what 10+ community members report using.
Based on 10+ community reports
View community protocolsResearch Tools
Before You Begin
Review safety warnings and contraindications before starting any protocol.
Preclinical Research Status#
Klotho peptides (KP1, KP6) are preclinical research compounds that have not been tested in humans. All dosing information below is derived from animal studies and is provided for research context only. No human dosing protocols exist.
Research Dosing in Animal Models#
KP1 for Kidney Fibrosis#
In the foundational study by Yuan et al. (Nature Communications 2022):
- Route: Intravenous injection in mice
- Model: Unilateral ureteral obstruction (UUO) kidney fibrosis
- Administration: IV bolus dosing
- Distribution: Preferential accumulation in injured kidneys observed
- Outcomes: Preserved kidney function, repressed TGF-beta signaling, ameliorated renal fibrosis, restored endogenous klotho expression
KP1 has also been studied in ischemia-reperfusion injury models, where it inhibited cellular senescence in the fibrotic kidney by restoring klotho expression via posttranscriptional regulation.
KP6 for Diabetic Kidney Disease#
In the study by Zhou et al. (Kidney International 2022):
- Route: Chronic infusion in mice
- Models: STZ-induced type 1 diabetes and db/db type 2 diabetes
- Duration: Multiple weeks of treatment
- Outcomes: Reversed proteinuria, attenuated glomerular hypertrophy, mitigated podocyte damage, ameliorated fibrotic lesions
- Control: Scrambled-sequence KP6 showed no therapeutic effect
Klotho Protein for Cognitive Enhancement#
For the full KL1 domain (not KP1/KP6 peptides):
In Castner et al. (Nature Aging 2023):
- Route: Single systemic injection in aged rhesus macaques
- Dose: Low-dose klotho protein (specific dose in mcg/kg not publicly specified)
- Key finding: Low dose enhanced cognition; high dose did not
- Onset: Cognitive enhancement observed within 4 hours
- Duration: Effects persisted for approximately 2 weeks
Limitations of Preclinical Dosing Data#
Several critical factors prevent translation of animal dosing to human use:
- No human PK data: Pharmacokinetic parameters for klotho peptides in humans are completely unknown
- Species differences: Peptide metabolism, distribution, and receptor binding may differ significantly between rodents and humans
- Route challenges: IV injection and chronic infusion used in preclinical studies require adaptation for clinical use
- Dose-response: KP1 and KP6 dose-response relationships have not been fully characterized even in animal models
- Peptide stability: In vivo half-life and proteolytic degradation rates not formally established
No Commercial Products Available#
Klotho peptides are not available as dietary supplements, injectable peptides, or any other consumer product. Research-grade KP1 and KP6 are available from specialty peptide suppliers (Tocris, Cayman Chemical) for laboratory research only. Products marketed as "klotho supplements" do not contain actual klotho-derived peptides.
Dosing Context#
Klotho Peptides belongs to the Anti-Aging category of research peptides. Dosing protocols for Klotho Peptides are derived from available clinical trial data. These protocols are provided for research reference only and do not constitute medical advice. Actual dosing decisions should be made by qualified healthcare providers based on individual patient factors.
Research Protocols#
The following dosing protocols have been documented in clinical research for Klotho Peptides:
Preclinical Kidney Fibrosis (KP1 - Intravenous)#
Dose: In mouse unilateral ureteral obstruction (UUO) models, KP1 was administered intravenously. Doses were not specified in standardized human-equivalent terms. KP1 showed preferential accumulation in injured kidneys after IV administration.
Frequency: IV injection in preclinical models
Duration: Acute and short-term dosing in fibrosis models
Published in Nature Communications (2022). Not applicable to human use. Route and dose optimization for human application has not been determined.
Preclinical Diabetic Kidney Disease (KP6 - Chronic Infusion)#
Dose: In diabetic mouse models (STZ-induced and db/db), KP6 was administered by chronic infusion. Treatment reversed established proteinuria and ameliorated glomerulosclerosis and interstitial fibrosis.
Frequency: Chronic infusion in preclinical models
Duration: Multiple weeks in diabetic mouse models
Published in Kidney International (2022). Scrambled-sequence control peptide showed no effect, confirming sequence-specific activity.
Reconstitution and Preparation#
Research-grade klotho peptides (KP1, KP6) are supplied as lyophilized powder by specialty peptide suppliers. Reconstitute in sterile water or appropriate buffer according to supplier instructions. These are research reagents, not pharmaceutical products.
Storage Requirements#
Store lyophilized peptides at -20 degrees C, protected from light and moisture. Reconstituted solutions should be aliquoted and stored at -20 degrees C to avoid freeze-thaw degradation. Follow supplier-specific storage recommendations.
Tools & Resources#
Calculate your exact dose -- Use the Dosing Calculator to convert vial concentrations to injection volumes for peptide research.
Building a multi-peptide protocol? -- Try the Protocol Schedule Builder to plan your research timeline with klotho peptides alongside other anti-aging compounds.
Check stack compatibility -- Verify klotho peptide interactions with your other peptides using the Stack Compatibility Checker.
Related Dosing Guides#
- Epitalon Dosing Protocols -- Telomere-targeted anti-aging peptide with established cycling protocols
- GHK-Cu Dosing Protocols -- Copper peptide for tissue repair and skin rejuvenation
- NAD+ Dosing Protocols -- Cellular energy and longevity support
- SS-31 Dosing Protocols -- Mitochondria-targeted peptide for age-related decline
Compare Klotho Peptides#
- Klotho Peptides vs Epitalon -- Compare anti-aging mechanisms: klotho (kidney/cognition) vs epitalon (telomeres)
- Klotho Peptides vs GHK-Cu -- Tissue repair pathways compared
- Klotho Peptides vs SS-31 -- Systemic aging vs mitochondrial targeting
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Protocol updates
Get notified when we update dosing protocols or publish related comparisons.
Frequently Asked Questions About Klotho Peptides
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.